Abstract
Aim: We explored 2-year outcomes in a sample of clinical high risk (CHR) patients who converted to psychosis despite receiving interventions. Methods: Of 167 CHR patients, 18 had converted to psychosis and received treatment for their first episode of psychosis in an early intervention service over 2 years. Results: Compared to patients admitted directly to the same early intervention service without having been identified as CHR prior to onset of psychosis, CHR converters were in remission for fewer months (M = 5 vs M = 10); were more likely to be prescribed more than 1 antipsychotic medication (90% vs 68%) and to receive clozapine treatment (38% vs 2%) over 2 years. Conclusions: CHR patients who convert to psychosis may be inherently more resistant to comprehensive treatment and may have poorer outcomes. Conversion to psychosis from a state of CHR can be reduced to a rate of 10%–12% following interventions, yet outcomes for patients who convert despite such interventions remain unexplored.
| Original language | English |
|---|---|
| Pages (from-to) | 715-719 |
| Number of pages | 5 |
| Journal | Early Intervention in Psychiatry |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2018 |
Bibliographical note
Funding Information:Ashok Malla is funded through the Canada Research Chair Program. He has also received research funding, unrelated to the present study, from BMS, Pfizer, Otsuka and Lundbeck as well as honoraria related CME lectures and advisory board participation from BMS; Otsuka, Sunnovian, Lundbeck and Pfizer. Gerald Jordan has received funds to support his graduate studies from the Department of Psychiatry at McGill University; Fonds de recherce Santé Québec; and the Canadian Institutes of Health Research. Ridha Joober sits on the advisory boards and speakers’ bureaus of Pfizer, Janssen Ortho, BMS, Sunovion, Otsuka and Lundbeck; he has received grant funding from them and from AstraZeneca. He has received honoraria from Janssen Canada, Shire, Lundbeck, Otsuka and from Pfizer Canada for CME presentations and royalties for Henry Stewart talks. Marianne de Bonneville, Jai Shah, Kia Faridi, Srividya Iyer and Mark Rabinovitch have no interests to declare.
Funding Information:
information Canada Research Chair Program; BMS; Pfizer; Otsuka; Lundbeck; Department of Psychiatry at McGill University; Fonds de recherce Sant? Qu?bec; Canadian Institutes of Health Research; Janssen Ortho; Sunovion; AstraZeneca.Ashok Malla is funded through the Canada Research Chair Program. He has also received research funding, unrelated to the present study, from BMS, Pfizer, Otsuka and Lundbeck as well as honoraria related CME lectures and advisory board participation from BMS; Otsuka, Sunnovian, Lundbeck and Pfizer. Gerald Jordan has received funds to support his graduate studies from the Department of Psychiatry at McGill University; Fonds de recherce Sant? Qu?bec; and the Canadian Institutes of Health Research. Ridha Joober sits on the advisory boards and speakers? bureaus of Pfizer, Janssen Ortho, BMS, Sunovion, Otsuka and Lundbeck; he has received grant funding from them and from AstraZeneca. He has received honoraria from Janssen Canada, Shire, Lundbeck, Otsuka and from Pfizer Canada for CME presentations and royalties for Henry Stewart talks. Marianne de Bonneville, Jai Shah, Kia Faridi, Srividya Iyer and Mark Rabinovitch have no interests to declare.
Publisher Copyright:
© 2017 John Wiley & Sons Australia, Ltd
Keywords
- clinical high risk for psychosis
- clozapine
- first-episode psychosis
- outcome
- remission
ASJC Scopus subject areas
- Phychiatric Mental Health
- Psychiatry and Mental health
- Biological Psychiatry
